Anti-Mouse TREM2 – Fc Muted (mAbMods)

Product No.: T721

- -
- -
Product No.T721
Clone
178 (LALAPG)
Product Type
Recombinant Monoclonal Antibody
Alternate Names
Triggering receptor expressed on myeloid cells 2
Isotype
Mouse IgG2a
Applications
B
,
ELISA
,
FA
,
FC
,
in vivo

- -
- -
Select Product Size
- -
- -

Antibody Details

Product Details

Reactive Species
Mouse
Host Species
Mouse
Recommended Isotype Controls
Immunogen
ectodomain of TREM2
Product Concentration
≥ 5.0 mg/ml
Endotoxin Level
≤ 1.0 EU/mg as determined by the LAL method
Purity
≥95% by SDS Page
≥95% monomer by analytical SEC
Formulation
This monoclonal antibody is aseptically packaged and formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.2 - 7.4 with no carrier protein, potassium, calcium or preservatives added. Due to inherent biochemical properties of antibodies, certain products may be prone to precipitation over time. Precipitation may be removed by aseptic centrifugation and/or filtration.
State of Matter
Liquid
Product Preparation
Functional grade preclinical antibodies are manufactured in an animal free facility using only in vitro protein free cell culture techniques and are purified by a multi-step process including the use of protein A or G to assure extremely low levels of endotoxins, leachable protein A or aggregates.
Storage and Handling
Functional grade preclinical antibodies may be stored sterile as received at 2-8°C for up to one year. For longer term storage, aseptically aliquot in working volumes without diluting and store at ≥ -80°C. Avoid Repeated Freeze Thaw Cycles.
Regulatory Status
Research Use Only
Country of Origin
USA
Shipping
2 - 8°C Wet Ice
Additional Applications Reported In Literature ?
FA,
B,
ELISA,
FC
Each investigator should determine their own optimal working dilution for specific applications. See directions on lot specific datasheets, as information may periodically change.

Description

Specificity
178 (LALAPG) activity is directed against mouse TREM2.
Antigen Distribution
In healthy tissues, TREM2 is expressed on myeloid cells (microglia and osteoclasts), infiltrating macrophages, and a small set of tissue-specific macrophages in the brain, adipose, adrenal gland, skin, alveola, endometrium, and placenta. TREM2 is also expressed by tumor-infiltrating macrophages.
Background
TREM2 is a transmembrane receptor in the immunoglobulin superfamily which has a short cytosolic tail that lacks signal transduction and trafficking motifs1. TREM2 initiates intracellular signaling by interacting with the adaptor proteins DNAX activation protein 12 (DAP12) and DAP10, which are phosphorylated to recruit signal transduction machinery when ligands bind. TREM2 interacts with a wide array of anionic ligands, including bacterial products such as lipopolysaccharide and dextran sulfates, DNA, lipoproteins, apolipoproteins, phospholipids1 and amyloid-β oligomers2.

In healthy tissues, TREM2 is involved in tissue development and maintenance, synaptic pruning1, central nervous system homeostasis2, the hair follicle stem cell niche1, and activates immune remodeling when tissue damage is detected1. When dysregulated, TREM2 affects a variety of pathologies including neurodegeneration, fatty liver disease, obesity, atherosclerosis, and tumor microenvironment and development. In Alzheimer’s Disease, TREM2 activation initiates a signaling loop that promotes its own ligand production, sustains microglial responses, and leads to disease progression1, 2, 3. Defects in TREM2 also cause polycystic lipomembranous osteodysplasia with sclerosing leukoencephalopathy (PLOSL), a fatal disease of pre-senile dementia1. Additionally, Trem2 knockout mice are more resistant to cancer growth and are more responsive to anti-PD1 immunotherapy than wild-type mice3. Given its broad role in pathology, TREM2 is a target of immunotherapy.

Clone 178 was generated by immunizing a Wister rat with a recombinant protein consisting of the ectodomain of TREM2 fused to the human Ig constant domain4. Spleen cells were harvested, fused with Sp2/0 myeloma cells, and the resulting hybridomas screened against Jurkat cells transiently infected with TREM2. A recombinant form of 178 was then generated, in which the variable region of the heavy chain was grafted onto a mouse IgG2a constant region backbone containing a mutated Fc domain (LALAPG)3. The LALAPG mutation prevents recognition by Fc receptors and complement, thereby minimizing antibody-dependent cellular cytotoxicity and antibody-dependent phagocytosis.

Clone 178 blocks ligand binding to TREM23 and does not cross-react with TREM14.

Antigen Details

Ligand/Receptor
DAP12
NCBI Gene Bank ID
UniProt.org
Q99NH8
Research Area
Innate Immunity
.
Neuroscience

References & Citations

1. Deczkowska A, Weiner A, Amit I. Cell. 181(6):1207-1217. 2020.
2. Zhao P, Xu Y, Fan X, et al. MAbs. 14(1):2107971. 2022.
3. Molgora M, Esaulova E, Vermi W, et al. Cell. 182(4):886-900.e17. 2020.
4. Turnbull IR, Gilfillan S, Cella M, et al. J Immunol. 177(6):3520-3524. 2006.
B
Indirect Elisa Protocol
FA
Flow Cytometry
in vivo Protocol

Formats Available

- -
- -
Products are for research use only. Not for use in diagnostic or therapeutic procedures.